Wistar receives grant to further research by Wistar scientists Rauscher and Chen

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Frank Rauscher
Qing Chen

The Jayne Koskinas Ted Giovanis Foundation for Health and Policy awarded The Wistar Institute a $840,000 grant over three years, to support the Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium at Wistar.

The award furthers the multidisciplinary research projects of two Wistar scientists, Frank Rauscher, the principal investigator of the award, and Qing Chen, whose integrated research targets breast cancer and specifically how cancer cells migrate from the primary tumor to form an often-deadly metastasis.

Rauscher, professor in Wistar’s Gene Expression and Regulation Program, studies the regulation of gene expression in cellular differentiation and homeostasis and how disruption of these mechanisms affects tumor initiation and metastatic progression.

Chen, assistant professor in Wistar’s Immunology, Microenvironment and Metastasis Program, focuses on the molecular mechanisms of brain metastasis originating from primary tumors like breast cancer.

Working in collaboration, the scientists will focus their breast cancer research at the mechanisms used by the tumor at the very onset of the metastatic process, and how the primary tumor burden promotes and activates metastasis to distant organs— specifically in the brain. They hope to understand and define the biochemical mechanisms specific to cancer cells that promote metastasis and to find druggable targets to block tumor spread.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login